Application of antisense oligonucleotide in the treatment of inherited retinal dystrophy
10.3760/cma.j.cn115989-20210128-00074
- VernacularTitle:反义寡核苷酸技术在遗传性视网膜变性治疗中的应用
- Author:
Wuyi LI
1
;
Ruifang SUI
Author Information
1. 中国医学科学院 北京协和医学院 北京协和医院眼科 100730
- Keywords:
Oligonucleotides, antisense;
Genetic therapy;
Retinal dystrophies, inherited
- From:
Chinese Journal of Experimental Ophthalmology
2022;40(1):67-72
- CountryChina
- Language:Chinese
-
Abstract:
Gene therapy is expected to restore the function of genetic material fundamentally and it has become a new trend in inherited retinal dystrophy treatment.Antisense oligonucleotide (AON) is a kind of small molecule nucleic acid drug, which can specifically bind to messenger RNA through the base pairing principle, thus interfering or modifying gene expression at the transcription and translation level.Possessing the advantages of high specificity and efficiency, wide targeting range, low immunogenicity and limited adverse effect, AON has become a novel remedy for inherited retinal dystrophy.Currently, three different AON drugs have already been used in clinical trials for inherited retinal dystrophy.In this review, the chemical structure modification, properties and mechanism of AON, and the therapeutic strategies of AON in different inherited retinal dystrophy diseases in recent years were summarized.
